My Treatment Approach: HER2+ Breast Cancer : Episode 7
Opinion
Video
TKI Regimens and Other Novel Approaches in Later Line Treatment of HER2+ mBC Setting
Author(s):
Vijayakrishna Gadi, MD, PhD, shares his insights on managing patients with HER2-positive metastatic breast cancer who have progressed on second and third-line treatments, stressing the potential benefits of incorporating small molecules, tyrosine kinase inhibitors (TKIs), chemotherapy, and enrolling patients in clinical trials to optimize outcomes.
EP: 1.The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients
EP: 2.Evolution of the HER2+ Metastatic Breast Cancer Treatment Landscape
EP: 3.First-Line HER2+ Metastatic Breast Cancer Trials in Focus
EP: 4.Case Study: Treatment Sequencing for a 62 Year Old Woman with HER2+ Metastatic Breast Cancer After Progression on T-DXd
EP: 5.Evidence-Based Sequencing for HER2+ mBC After Progression: Clinical Trial Data and NCCN Guideline Updates
EP: 6.Managing Adverse Events and Toxicities HER2+ Metastatic Breast Cancer
Now Viewing
EP: 7.TKI Regimens and Other Novel Approaches in Later Line Treatment of HER2+ mBC Setting
EP: 8.Case Study of a 54-Year-Old Woman With HER2+ Metastatic Breast Cancer and Brain Metastases: Optimal Treatment Approaches
EP: 9.Exploring the Latest Updates from the HER2CLIMB Trial Evaluating Tucatinib in Patients with Brain Metasteses
EP: 10.Managing Brain Metastases in HER2+ Metastatic Breast Cancer: Clinical Trial Data and Multidisciplinary Approaches
EP: 11.Evolving Treatment Paradigm in HER+ Breast Cancer: Future Directions
Video content above is prompted by the following questions:
- For patients who progress through multiple HER2-targeted therapies, when would you consider chemotherapy and what specific regimens?
- Are there data supporting the use of continuing HER2 blockade with chemotherapy in later lines?
Related Videos
Related Content
